BW
BCRX icon

Bison Wealth’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bison Wealth’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1.15M Hold
153,280
– – 0.25% 79
2024
Q3 		$1.16M Buy
153,280
+1,265
+0.8% +$9.62K 0.19% 123
2024
Q2 		$772K Hold
152,015
– – 0.13% 168
2024
Q1 		$772K Hold
152,015
– – 0.13% 168
2023
Q4 		$911K Buy
152,015
+1,000
+0.7% +$5.79K 0.16% 141
2023
Q3 		$1.07M Hold
151,015
– – 0.21% 118
2023
Q2 		$1.06M Buy
+151,015
New +$1.21M 0.2% 126

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bison Wealth's BCRX Position: Q4 2024 in Review

Bison Wealth held its BioCryst Pharmaceuticals (BCRX) position steady in Q4 2024 at 153,280 shares worth $1.15M. The position accounts for 0.25% of the portfolio, ranked #79.

Bison Wealth first reported a position in BCRX in Q2 2023 and has held it in 7 quarters since. The position peaked at $1.16M in Q3 2024. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

  • Bison Wealth held 153,280 shares of BioCryst Pharmaceuticals worth $1.15M as of Q4 2024.
  • Bison Wealth left its BioCryst Pharmaceuticals share count unchanged in Q4 2024.
  • BioCryst Pharmaceuticals made up 0.25% of Bison Wealth's portfolio in Q4 2024, its #79 holding.
  • Bison Wealth first reported a position in BioCryst Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
  • Bison Wealth's BioCryst Pharmaceuticals position peaked at $1.16M in Q3 2024.
  • 258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on Bison Wealth's 13F filing for Q4 2024, filed 14 Feb 2025.